ASH 2024 – Matthew S. Davids
Matthew S. Davids provides insights into the potential of the new drug class of protein degraders in CLL treatment and discusses recently identified biomarkers that are prognostic or predictive in the era of targeted therapy. He also evaluates the performance of BTK-inhibitor-based treatments in high-risk CLL or after prior exposure to targeted agents and explores strategies to overcome real-world barriers to guideline- and evidence-based care in CLL.
